SARS-CoV-2 vaccines-induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?
Rev. saúde pública (Online)
; 55: 1-6, 2021.
Article
em En
| LILACS, BBO
| ID: biblio-1347806
Biblioteca responsável:
BR1.1
ABSTRACT
ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
BBO
/
LILACS
Assunto principal:
Trombocitopenia
/
Trombose
/
Vacinas
/
COVID-19
Limite:
Humans
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. saúde pública (Online)
Assunto da revista:
Sa£de P£blica
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Alemanha
/
Nigéria
País de publicação:
Brasil